Wedbush Has Bearish Forecast for ASND FY2027 Earnings

Ascendis Pharma A/S (NASDAQ:ASND) – Stock analysts at Wedbush reduced their FY2027 earnings per share estimates for Ascendis Pharma A/S in a report issued on Thursday, January 16th. Wedbush analyst Y. Zhong now expects that the biotechnology company will earn $3.37 per share for the year, down from their previous estimate of $3.59. Wedbush has a “Outperform” rating and a $181.00 price objective on the stock. The consensus estimate for Ascendis Pharma A/S’s current full-year earnings is ($7.27) per share. Wedbush also issued estimates for Ascendis Pharma A/S’s FY2028 earnings at $8.78 EPS.

Other analysts have also issued reports about the company. JPMorgan Chase & Co. decreased their price objective on Ascendis Pharma A/S from $180.00 to $174.00 and set an “overweight” rating on the stock in a research note on Wednesday, October 23rd. TD Cowen cut their target price on shares of Ascendis Pharma A/S from $160.00 to $153.00 and set a “buy” rating for the company in a research report on Friday, November 15th. UBS Group started coverage on shares of Ascendis Pharma A/S in a research note on Tuesday, January 7th. They issued a “buy” rating and a $196.00 price objective for the company. Stifel Nicolaus increased their price objective on Ascendis Pharma A/S from $200.00 to $207.00 and gave the company a “buy” rating in a research note on Friday, November 15th. Finally, StockNews.com upgraded Ascendis Pharma A/S from a “sell” rating to a “hold” rating in a report on Wednesday, November 20th. Two investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus price target of $192.07.

Ascendis Pharma A/S Stock Up 2.3 %

Shares of NASDAQ:ASND opened at $131.06 on Monday. Ascendis Pharma A/S has a twelve month low of $111.09 and a twelve month high of $161.00. The firm has a market capitalization of $7.95 billion, a PE ratio of -16.22 and a beta of 0.65. The company has a 50-day moving average price of $133.19 and a two-hundred day moving average price of $133.40.

Hedge Funds Weigh In On Ascendis Pharma A/S

Several large investors have recently made changes to their positions in the business. Wilmington Savings Fund Society FSB bought a new stake in shares of Ascendis Pharma A/S in the 3rd quarter valued at approximately $30,000. Groupama Asset Managment purchased a new stake in Ascendis Pharma A/S in the third quarter worth $60,000. GAMMA Investing LLC boosted its holdings in shares of Ascendis Pharma A/S by 58.0% in the fourth quarter. GAMMA Investing LLC now owns 583 shares of the biotechnology company’s stock valued at $80,000 after purchasing an additional 214 shares during the period. Signaturefd LLC grew its position in shares of Ascendis Pharma A/S by 13.2% during the 3rd quarter. Signaturefd LLC now owns 686 shares of the biotechnology company’s stock worth $102,000 after buying an additional 80 shares in the last quarter. Finally, Rhumbline Advisers increased its position in Ascendis Pharma A/S by 10.3% during the 2nd quarter. Rhumbline Advisers now owns 1,533 shares of the biotechnology company’s stock valued at $209,000 after purchasing an additional 143 shares during the period.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.